Giant Cell Tumor of Bone in Patients 55 Years and Older A Study of 34 Patients

被引:2
|
作者
Broehm, Cory J. [1 ]
Inwards, Carrie Y. [1 ]
Al-Ibraheemi, Alyaa [1 ]
Wenger, Doris E. [2 ]
Jenkins, Sarah M. [3 ]
Jin, Long [1 ]
Oliveira, Andre M. [1 ]
Zreik, Riyam T. [4 ]
Carter, Jodi M. [1 ]
Boland, Jennifer M. [1 ]
Fritchie, Karen J. [1 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[2] Mayo Clin, Dept Radiol, Rochester, MN USA
[3] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA
[4] Baylor Scott & White Hlth, Dept Pathol, Temple, TX USA
关键词
Giant cell tumor of bone; Bone tumors; Elderly; H3F3A; ONCOGENES; SWEDEN; USP6;
D O I
10.1093/AJCP/AQX155
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: Most giant cell tumors of bone (GCTs) occur in patients aged 20 to 40 years. We analyzed features of GCT in patients 55 years or older. Methods: GCTs were examined for fibrosis, matrix, cystic change, histiocytes, mitoses, and necrosis. Clinical/radiologic data were collected. Results: Thirty-four (5%) of 710 GCTs occurred in patients older than 55 years (14/20 male/female; 56-83 years) in long bones (n = 24), vertebrae (n = 6), pelvis (n = 3), and metacarpal (n = 1). Imaging was classic in 26 of 27 cases; one case appeared malignant. Morphologic patterns included fibrosis (n = 29), bone formation (n = 19), cystic change (n = 8), necrosis (n = 8), foamy histiocytes (n = 7), and secondary aneurysmal bone cyst formation (n = 1). Mitoses ranged from 0 to 18 per 10 high-power fields. Six recurred; one patient developed metastasis. Four of five cases harbored H3F3A mutations. Conclusions: GCTs in patients 55 years or older share pathologic characteristics with those arising in younger adults. Fibrosis and reactive bone are common, potentially leading to diagnostic confusion in this population. No histologic features correlate with adverse outcome.
引用
收藏
页码:222 / 233
页数:12
相关论文
共 50 条
  • [31] Symplastic/pseudoanaplastic giant cell tumor of the bone
    Sarungbam, Judy
    Agaram, Narasimhan
    Hwang, Sinchun
    Lu, Chao
    Wang, Lu
    Healey, John
    Hameed, Meera
    SKELETAL RADIOLOGY, 2016, 45 (07) : 929 - 935
  • [32] RANKL, denosumab, and giant cell tumor of bone
    Thomas, David M.
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (04) : 397 - 403
  • [33] Giant cell tumor of bone and secondary osteoarthritis
    Todi, Niket
    Hiltzik, David M.
    Moore, Drew D.
    HELIYON, 2024, 10 (10)
  • [34] Radiotherapy in the Management of Giant Cell Tumor of Bone
    Shi, Wenyin
    Indelicato, Daniel J.
    Reith, John
    Smith, Kristy B.
    Morris, Christopher G.
    Scarborough, Mark T.
    Gibbs, Charles P., Jr.
    Mendenhall, William M.
    Zlotecki, Robert A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (05): : 505 - 508
  • [35] Giant cell tumor of bone-an update
    Tschavoll, Felix
    Lutteri, Gianluca
    Leinauer, Benedikt
    Mellert, Kevin
    Moeller, Peter
    Barth, Thomas F. E.
    PATHOLOGIE, 2023, 44 (03): : 215 - 219
  • [36] Symplastic/pseudoanaplastic giant cell tumor of the bone
    Judy Sarungbam
    Narasimhan Agaram
    Sinchun Hwang
    Chao Lu
    Lu Wang
    John Healey
    Meera Hameed
    Skeletal Radiology, 2016, 45 : 929 - 935
  • [37] Denosumab for the treatment of giant cell tumor of the bone
    Brodowicz, Thomas
    Hemetsberger, Margit
    Windhager, Reinhard
    FUTURE ONCOLOGY, 2015, 11 (13) : 1881 - 1894
  • [38] Giant-cell tumor of bone in 2022
    Larousserie, Frederique
    Audard, Virginie
    Burns, Robert
    de Pinieux, Gonzague
    ANNALES DE PATHOLOGIE, 2022, 42 (03) : 214 - 226
  • [39] Perigeniculate Giant Cell Tumor of Temporal Bone
    Babajanian, Eric E.
    Hollon, Todd C.
    Seasor, Tori A.
    Couldwell, William
    Gurgel, Richard K.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [40] Cyclin alterations in giant cell tumor of bone
    Kauzman, A
    Li, SQ
    Bradley, G
    Bell, RS
    Wunder, JS
    Kandel, R
    MODERN PATHOLOGY, 2003, 16 (03) : 210 - 218